MedTrace Logo

An Observational Study to Assess the Effect of Cumulative Ribavirin Dose in Participants With Chronic Hepatitis C

NCT02557646 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 697

Last updated 2016-03-28

Study results available
· View outcomes & findings →

Summary

The purpose of this open-label, non-randomized, single-arm, multicentre observational study is to investigate the influence of the cumulative dose (total administered dose/ planned dose) of ribavirin on the sustained virologic response (SVR) in participants who have been receiving combination therapy with pegylated interferon alfa-2a (Pegasys) and ribavirin (Copegus).

Conditions

  • Hepatitis C, Chronic

Interventions

BIOLOGICAL

Peginterferon alfa-2a

Participants received pegylated interferon subcutaneous injection in accordance with current guidelines and SPCs.P

DRUG

Ribavirin

Participants received ribavirin 200 mg film-coated tablet in accordance with current guidelines and SPCs.

Sponsors & Collaborators

Principal Investigators

  • Clinical Trials · Hoffmann-La Roche

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-05-31
Primary Completion
2014-03-31
Completion
2014-03-31

Countries

  • Hungary

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02557646 on ClinicalTrials.gov